Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7-Blocking Therapy in Inflammatory Bowel Disease
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Predicting inflammatory bowel disease treatment response is crucial. A specific T-cell signature in nonresponders before vedolizumab therapy may predict treatment outcomes, aiding personalized medicine.
Area Of Science
- Immunology
- Gastroenterology
- Precision Medicine
Background
- Biological therapies like vedolizumab are effective for inflammatory bowel disease (IBD).
- Predicting patient response to IBD therapies remains a significant clinical challenge.
- Reliable biomarkers are needed to guide personalized treatment strategies for IBD.
Purpose Of The Study
- To identify predictors of treatment response to vedolizumab in IBD patients.
- To comprehensively assess vedolizumab-induced immunologic changes.
- To develop a predictive classifier for personalized IBD management.
Main Methods
- Prospective sampling of two IBD patient cohorts receiving vedolizumab.
- Multi-omic analysis including mass cytometry, scRNA-seq, BCR/TCR-seq, and proteomics.
- Machine learning integration of multimodal data to identify predictive signatures.
Main Results
- Vedolizumab induced significant alterations in circulating immune cell populations and T-cell receptor diversity.
- A distinct signature of proliferating CD4+ memory T cells was identified in nonresponders prior to treatment.
- This signature indicated an activated T-helper 1/T-helper 17 phenotype with elevated integrin α4β1.
Conclusions
- A reliable predictive classifier for vedolizumab response in IBD was identified.
- The findings have significant implications for personalizing IBD treatment strategies.
- Understanding T-cell phenotypes can guide future therapeutic development.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...